Effect of allopurinol on caffeine disposition in man.
Caffeine (5 mg kg-1) was administered orally to two healthy, non-smoking subjects on three separate occasions--before, and during therapy with the xanthine oxidase inhibitor allopurinol at doses of either 300 or 600 mg daily. Plasma and urinary levels of methylxanthines, endogenous oxypurines and allopurinol and its metabolite oxypurinol were measured using h.p.l.c. analyses. Allopurinol treatment caused a specific, dose-dependent inhibition of the conversion of the caffeine metabolite 1-methylxanthine (1X) to 1-methyluric acid (1U). A good correlation was observed in both subjects between the urinary 1U/1X molar ratio and the ratio of endogenous urate to hypoxanthine + xanthine at the different allopurinol doses, supporting the proposal that the 1U/1X molar ratio after caffeine intake provides an in vivo index of xanthine oxidase activity in man.
D000328:Adult; D000493:Allopurinol / Q000008:administration & dosage / Q000494:pharmacology*; D001711:Biotransformation / Q000187:drug effects; D002110:Caffeine / Q000008:administration & dosage / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D007700:Kinetics; D008297:Male; D014527:Uric Acid / Q000031:analogs & derivatives / Q000378:metabolism; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors; D014970:Xanthines / Q000378:metabolism
D014970:Xanthines; D014527:Uric Acid; C008514:methylxanthine; C030530:1-methyluric acid; D002110:Caffeine; D000493:Allopurinol; D014969:Xanthine Oxidase